Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center

• Published in: Journal of endocrinological investigation 2022-10, Vol.45 (10), p.1977-1990
• Main Authors: Rodríguez de Vera Gómez, P., García-González, J. J., Ravé-García, R., López Ruiz, R., Torres-Cuadro, A., Eichau-Madueño, S., García-García, C., Martín-Hernández, T.
• Format: Article
• Language: English
• Subjects: Diagnosis; Endocrinology; Graves disease; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Monoclonal antibodies; Multiple sclerosis; Observational studies; Original Article; Patients; Risk factors; Thyroid diseases; Thyroid gland; Thyroid-stimulating hormone; Thyroidectomy
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-022-01832-4

Objectives Graves’ disease induced by Alemtuzumab (GD-IA) is one of the most frequently observed adverse events in patients with multiple sclerosis (MS) treated with this drug. The aim of this study is the sequencing and description of these events, along with the identification of the risk factors leading to their development. Materials and methods We conducted a retrospective observational study identifying patients with relapsing–remitting multiple sclerosis (RRMS) and GD-IA, studying their baseline clinical features and variables related to the natural history of the disease. Results A total of 121 participants treated with Alemtuzumab were included, of whom 41 developed GD-IA (33.9%). A higher percentage of first-degree relatives with autoimmune thyroid disease was documented in the subgroup who developed the abovementioned event (14.6% vs 1.5%; p